Show simple item record

dc.contributor.authorde Faria e Silva, Ana L.
dc.contributor.authorRyder, Alan G.
dc.date.accessioned2023-05-11T08:03:38Z
dc.date.available2023-05-11T08:03:38Z
dc.date.issued2022-09-07
dc.identifier.citationde Faria e Silva, Ana L., & Ryder, Alan G. (2022). Analyzing protein conjugation reactions for antibody-drug conjugate synthesis using polarized excitation emission matrix spectroscopy. Biotechnology and Bioengineering, 119(12), 3432-3446. doi:https://doi.org/10.1002/bit.28229en_IE
dc.identifier.issn1097-0290
dc.identifier.urihttp://hdl.handle.net/10379/17769
dc.description.abstractAntibody-drug conjugates (ADCs) are promising anticancer therapeutics, which offer important advantages compared to more classical therapies. There are a variety of ADC critical quality attributes (CQAs) such as the protein structure, aggregation, and drug-to-antibody ratio (DAR), which all impact on potency, stability, and toxicity. Production processes can destabilize antibodies via a variety of physical and chemical stresses, and or by increased aggregation after conjugation of hydrophobic drugs. Thus, a proper control strategy for handling, production, and storage is necessary to maintain CQA levels, which requires the use of in-process quality measurements to first identify, then understand, and control the variables which adversely affect ADC CQAs during manufacturing. Here, we show how polarized excitation emission matrix (pEEM) spectroscopy, a sensitive, nondestructive, and potentially fast technique, can be used for rapidly assessing aggregation and DAR in a single measurement. pEEM provides several sources of information for protein analysis: Rayleigh scatter for identifying aggregate/particle formation and fluorescence emission to assess chemical and structural changes induced by attachment of a linker and/or a small molecule drug payload. Here, we used a nontoxic ADC mimic (monoclonal antibody with linker molecule) to demonstrate efficacy of the measurement method. Emission changes caused via light absorption by the attached linker, allowed us to predict DAR with good accuracy using fluorescence signal from the final purified products (6% relative error of prediction [REP]) and also from unpurified alkylation intermediates (11% REP). pEEM changes could also be correlated with size (hydrodynamic radius, Rh) and aggregate content parameters obtained from dynamic light scattering and size exclusion chromatography (SEC). For the starting material and purified product samples, pEEM correlated better with Rh (R2¿=¿0.99, 6% REP) than SEC determined aggregate content (18% REP). Combining both fluorescence and light scatter signals also enabled in-process size quantification (6% REP). Overall, combining polarized measurements with EEM and Rayleigh scatter provides a single measurement, multi-attribute test method for ADC manufacturing.en_IE
dc.description.sponsorshipThis publication emanated from research supported in part by a Principal Investigator research grant (Grant Number 14/IA/2282) to Alan G. Ryder from Science Foundation Ireland and is cofunded under the European Regional Development Fund. 14/IA/2282, Advanced Analytics for Biological Therapeutic Manufacture, Science Foundation Ireland (SFI) with co-funding under the European Regional Development Fund. Open access funding provided by IReL.en_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherWileyen_IE
dc.relation.ispartofBiotechnology and Bioengineeringen
dc.rightsAttribution 4.0 International (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectantibody drug conjugateen_IE
dc.subjectconjugationen_IE
dc.subjectfluorescenceen_IE
dc.subjectmonoclonal antibodyen_IE
dc.subjectpolarizeden_IE
dc.titleAnalyzing protein conjugation reactions for antibody-drug conjugate synthesis using polarized excitation emission matrix spectroscopyen_IE
dc.typeArticleen_IE
dc.date.updated2023-05-10T10:58:44Z
dc.identifier.doi10.1002/bit.28229
dc.local.publishedsourcehttps://doi.org/10.1002/bit.28229en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funderScience Foundation Irelanden_IE
dc.contributor.funderEuropean Regional Development Funden_IE
dc.internal.rssid29772165
dc.local.contactAlan Ryder, School Of Chemistry, Room 213, Arts/Science Building, South Cam, Nui Galway. 2943 Email: alan.ryder@nuigalway.ie
dc.local.copyrightcheckedNo This is an open access publication...so not sure do we also host a copy on ARAN,
dc.local.versionPUBLISHED
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Investigator Programme/14/IA/2282/IE/Advanced Analytics for Biological Therapeutic Manufacture (AA-BTM)./en_IE
nui.item.downloads50


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)